Vijayakrishna K. Gadi, MD, PhD

Neil Iyengar, MD; Claudine Isaacs, MD; Virginia Kaklamani, MD; and Vijayakrishna Gadi, MD, PhD, share clinical pearls for the evolving treatment landscape of HER+ metastatic breast cancer.

Vijayakrishna Gadi, MD, PhD, presents the case of a 63-year-old woman with grade 3 HER+/HR- metastatic breast cancer.

Breast cancer experts discuss the importance of patient quality of life when considering treatment recommendations for HER2+ breast cancer.

Claudine Isaacs, MD, comments on the follow-up and monitoring for a patient similar to the case presentation with HER2+ breast cancer.

Experts in breast cancer discuss the management of visceral metastases in HER2+ breast cancer, and Vijayakrishna Gadi, MD, PhD, presents the case of a 50-year-old woman with HER+/HR- breast cancer.

Vijayakrishna Gadi, MD, PhD; Claudine Isaacs, MD; Virginia Kaklamani, MD; and Neil Iyengar, MD, share their approach to treating patients with HER+ breast cancer who have brain metastases.

Breast cancer experts review unmet needs in the management of HER2+ metastatic breast cancer and updates from the 2021 ASCO virtual meeting.

Neil Iyengar, MD, leads the discussion on the current standard of care and the sequencing of therapy for HER2+ metastatic breast cancer.

Key opinion leaders discuss recent advancements and future directions in the HER2+ breast cancer space.

Expert panelists react to polling questions and give their input on the management both symptomatic and asymptomatic interstitial lung disease in HER2+ breast cancer, also touching on this impact in the era of COVID-19.

Experts discuss the careful monitoring of potential interstitial lung disease symptoms, how they proceed if symptoms progress, and how they handle this in patients who are asymptomatic.

Experts in breast cancer respond to polling questions surrounding the recognition of pneumonitis and interstitial lung disease.

A panel of experts weighs in the challenges of optimally sequencing therapy for patients with HER2+ breast cancer.

Experts provide insights on clinical decision-making in the setting of patient with HER2+ breast cancer.

Key opinion leaders explore the appropriateness of prophylactic therapy for brain metastases and share their thoughts on best practices.

An expert panel of breast oncologists discusses factors they consider when deciding whether to screen a patient with HER2+ breast cancer for brain metastases.

Adam Brufsky, MD, PhD, presents the case of a 37-year-old woman with HER2+/HR- metastatic breast cancer and polls the audience about screening for brain metastases.

Insights into ongoing unmet needs in the individualized management of HR+ breast cancer and thoughts regarding future directions.

Role of the Breast Cancer Index genomic index in therapeutic decision-making in the extended adjuvant setting in HR+ breast cancer.

A review of NCCN-recommended genomic assays and their impact on the management of HR+ breast cancer.

Best practices for the appropriate and timely use of genomic assays in clinical practice for patients with HR+ breast cancer.

Discussion of predictive and prognostic markers used to guide treatment decision-making in HR+ breast cancer.

The goals of adjuvant therapy versus extended adjuvant therapy for early-stage HR+ breast cancer and current treatment options available for each approach.

Expansion of precision medicine approaches will play a key role in optimizing care and improving outcomes for breast cancer patients in 2017. Here we highlight some of the studies and FDA approvals we are most anxious to see in the coming year.